Press release content from PR Newswire. The AP news staff was not involved in its creation.
LumiThera Announces Top Line Data in the European Multi-Center, LIGHTSITE II Clinical Study to Treat Dry Age-Related Macular Degeneration
April 7, 2021 GMT
SEATTLE, April 7, 2021 /PRNewswire/ LumiThera Inc., a commercial stage medical device company delivering photobiomodulation (PBM) treatment for ocular disorders and disease, today announced positive findings in its LIGHTSITE II, multi-center clinical trial in dry Age-Related Macular Degeneration (AMD) patients.
The prospective, double-masked, randomized, multi-center, European Union post-marketing clinical trial, titled LIGHTSITE II, was conducted in eight leading retinal centers based in the United Kingdom, Germany, Spain, Italy and France. The objective was to treat dry AMD subjects over the course of three rounds of PBM sessions every four months with a duration of 10 months. The study was converted to a smaller pilot as some of th
LumiThera Announces Top Line Data in the European Multi-Center, LIGHTSITE II Clinical Study to Treat Dry Age-Related Macular Degeneration adnkronos.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from adnkronos.com Daily Mail and Mail on Sunday newspapers.
Published: Feb 10, 2021
SEATTLE, Feb 10, 2021 /PRNewswire/ LumiThera, Inc., a commercial stage medical device company delivering photobiomodulation (PBM) treatment for ocular disorders and diseases, today announced it has completed enrollment in its multi-center United States clinical study in non-neovascular (dry) Age-Related Macular Degeneration (AMD) patients.
The randomized, multi-center study, LIGHTSITE III, enrolled the last patient at the Byers Eye Institute at Stanford University in Palo Alto, CA with Principal Investigator, Diana Do, M.D. We are very pleased to be able to enroll the last subject in the Study! Initial efficacy data will be available in approximately 13 months, indicated Dr. Do. The study will continue to follow patients for up to 24 months.
(1)
SEATTLE, Feb. 16, 2021 /PRNewswire/ LumiThera Inc., a commercial stage medical device company offering a photobiomodulation (PBM) treatment for ocular damage and disease, today announced the interim data from the ELECTROLIGHT pilot study in dry AMD patients.
A total of 23 eyes from 15 subjects with intermediate Dry AMD were enrolled into the prospective clinical study and treated with PBM using the Valeda Light Delivery System (3 times per week for 3 weeks). Subjects were tested for safety and functional vision improvements using the Diopsys electroretinogram (ERG) device. ERG is a diagnostic test that measures the electrical activity of the retina of the eye in response to a light stimulus. All subjects were tested at weekly intervals for ERG function prior to the start of the next week of PBM treatments. An interim analysis was performed following the Month 1 study visit. The study was conducted by Dan Montzka, M.D. and Larry Perich, D.O. at the Perich Eye Center (New Por
/CNW/ LumiThera, Inc., a commercial stage medical device company delivering photobiomodulation (PBM) treatment for ocular disorders and diseases, today.